

Conclusions: Patupilone administered once q3w is safe and well tolerated. The preliminary antitumor response is promising in this previously treated, platinum- and taxane-resistant population.

910

POSTER

Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDox) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct)

D. Mutch¹, M. Orlando², T. Teneriello³, A. Gordon⁴, S. McMeekin⁵, T. Goss², D. Scribner⁶, R. Naumann⁷, A. Alvarez Secord³, Y. Wang².

¹Washington University, Dept. of OB GYN, St Louis, USA; ²Eli Lilly, Oncology, Indianapolis, USA; ³Texas Oncology, Austin, USA; ⁴Arizona GYN Oncology, Phoenix, USA; ⁵University of Oklahoma, Oncology, Oklahoma City, USA; ⁶Carilion GYN Oncology Assoc., Roanoke, USA; ⁷Carolinas Medical Center, Oncology, Charlotte, USA; ⁸Duke University Medical Center, Oncology, Durham, USA

Background: OC pts with progression (prog) during or within 6 months (m) from primary therapy (tx) are considered Pt-R. Inclusion of paclitaxel in 1st-line tx requires agents lacking cross-resistance to both paclitaxel and platinum compounds for pts with refractory disease. Given the promising phase II results with Gem, comparison to PLDox, an approved therapy, was warranted.

Material and methods: Pt eligibility for this multicenter, open-label, randomized phase III study included: age ≥ 18 years, recurrent Pt-R epithelial ovarian, fallopian tube or primary peritoneal carcinoma, Pt-based 1st line CT (≤ 2 prior regimens), measurable disease or CA-125 ≥ 100 U/L, adequate organ function, and ECOG PS 0-2. Pts were randomized to receive Gem 1000 mg/m²/d (30' infusion) on days 1 and 8 every 21 days or PLDox 50 mg/m² day 1 every 28 days. Treatment continued until prog or undue toxicity (tox). Pts had the option to cross (X-) over to the alternative regimen at disease prog, tox (after reversal to \leq grade 2), or a cumulative dose of PLDox of 500 mg/m². The primary end point was progression-free survival (PFS).

Results: Between July 2002 and May 2004, 195 pts were enrolled. Baseline characteristics (age, PS, type/response to prior tx, measurable disease) were balanced between arms. 65%/35% received 1/2 prior regimens.

Parameter	Gem (n = 99)	PLDox (n = 96)	P-value
Median of Cycles (range)	4 (1-21)	3 (1-13)	
ORR (CR+PR) (95%-CI)	7.1% (3.1-14.5%)	7.3% (3.2-14.9%)	
ORR in pts (n = 65/60) with measurable disease	10.7%	10.0%	
SD	50.5%	40.6%	
PD	36.3%	45.8%	
Clinical Benefit (CR+PR+SD) (95%-CI)	57.6% (47.2-67.3%)	47.9% (37.7-58.3%)	0.198 ^a
PFS, median (weeks) (95%-CI)	15.6 (10.6-9.7)	13.3 (8.6-17.4)	0.869 ^b

^aFisher's exact test; ^bLog-Rank test

Toxicity was generally mild on both arms. Grade 3/4 Neutropenia was more common on Gem (36% vs 18%) while grade 2/3 hand-foot syndrome (0% vs 19%) and mucositis (3% vs 18%) were more common on PLDox. Febrile neutropenia (2% vs 2%), grade 3 Thrombocytopenia (6% vs 4%), grade 2/4 fatigue (24% vs 19%), emesis (17% vs 15%), rash (6% vs 6%) rates were similar. Only one pt died from tx-related tox. ~60% of pts went on to receive X-over tx. Only pts initially on PLDox X-over due to tox (14 pts. vs 0).

Conclusions: GEM and PLDox have comparable efficacy in Pt-R OC. Tox patterns differ between arms (laboratory vs symptomatic), however they are manageable. Follow-up continues to assess X-over outcomes and survival.

911

POSTER

Expression of FLICE-like inhibitory protein (c-FLIP_L) is associated with ovarian cancer patient's chemoresistance

D. Mezzanzanica¹, S. Staurengo², M. Bagnoli¹, P. Alberti¹, E. Balladore¹, L. Lusa³, A. Ditto⁴, M. Barbareschi⁵, S. Pilotti², S. Canevari¹. ¹Istituto Nazionale Tumori, Experimental Oncology Department, Milan, Italy; ²Istituto Nazionale Tumori, Anatomy Pathology Department, Milan, Italy; ³FIRC Institute for Molecular Oncology, Milan, Italy; ⁴Istituto Nazionale Tumori, Surgery Department, Milan, Italy; ⁵Azienda Ospedaliera, Trento, Italy

Background: Ovarian carcinoma is a highly lethal malignancy that often becomes resistant to chemotherapy. Alterations in apoptotic signals and p53 status contribute to drug resistance. We recently showed that the apoptosis inhibitory protein c-FLIP_L is involved in resistance to CD95-mediated apoptosis in ovarian carcinoma cells with wild-type p53 and that there is a significant (P = 0.034) inverse relationship between c-FLIP_L expression in ovarian cancer specimens and p53 accumulation or mutation. **Material and methods:** Archival material from 74 stage III-IV ovarian cancer patients with known clinical history was analyzed for c-FLIP_L expression and p53 nuclear accumulation by immunohistochemistry and for p53 mutational status by automated DNA sequencing. P53 mutations were classified as missense or non-missense according to the functional state of the molecule. Statistical analyses were performed to discover possible significant correlation between c-FLIP_L expression and different clinical parameters including: patient's age, tumor histotype and grading, p53 mutational status, p53 nuclear accumulation and response to front-line treatment.

Results: The inverse relationship between c-FLIP_L expression and p53 mutation (P = 0.0094) as well as p53 nuclear accumulation (P = 0.037) that we observed in our preliminary study, was confirmed in this larger clinical case material. No correlation was observed with tumor histotype or grading, although in a tissue micro array including normal, borderline and stage I-IV tumors, c-FLIP_L was mainly expressed in borderline and stage I tumors. This discrepancy might be due to the fact that the new case material only includes stages III and IV tumors. Although the overall survival curves of patients expressing or not the molecule are not statistically significant (P = 0.08), the median survival of patients expressing c-FLIP_L is much shorter than that of patients not expressing the molecule (40 versus 53 months). This difference further increased if only patient carrying a functional active p53 were considered (median survival 40 versus 58 months). Among 34 patients not responding to platinum-based chemotherapy, 22 expressed c-FLIP_L.

Conclusion: These data support the significant role of c-FLIP_L in the regulation of apoptosis in ovarian cancer and, as a cell survival factor, in resistance to platinum-based chemotherapy. Data validation is ongoing on an independent case material including more than 100 tumors from patients at all stages of the disease and with known clinical history.

912

POSTER

The prediction of the response to chemotherapy and survival of patients with ovarian clear cell carcinoma by ABCF2 expression

Y. Hashiguchi¹, H. Tsuda², Y. Ito³, K. Ito⁴, N. Yaegashi⁴, M. Birrer⁵, Y. Ohashi³, R. Berkowitz⁶, H. Sako¹, S. Mok⁶. ¹Osaka City Sumiyoshi Hospital, Obstetrics and Gynecology, Osaka, Japan; ²Osaka City General Hospital, Gynecology, Osaka, Japan; ³University of Tokyo, School of Health Sciences and Nursing, Biostatistics/Epidemiology and Prevention Health Science, Tokyo, Japan; ⁴Tohoku University Graduate School of Medicine, Gynecology, Sendai, Japan; ⁵National Cancer Institute, Rockville, MD, USA; ⁶Brigham and Women's Hospital, Harvard Medical School, Gynecologic Oncology, Boston, MA, USA

Background: Ovarian clear cell adenocarcinoma (CC) generally shows little response to combination chemotherapy and the overall prognosis is poor. We previously reported that ABCF2 might be a new biomarker for CC using cDNA microarray analysis. In this study, we raised a polyclonal antibody directed against ABCF2 and evaluated the relationship between ABCF2 expression and the response to chemotherapy or overall survival (OS) in CC patients.

Materials and methods:

- 307 epithelial ovarian cancer (Serous: 93; Mucinous: 46; Endometrioid: 56; CC: 80; Undifferentiated: 32) were included in this study. ABCF2 expression was investigated by immunohistochemistry in each histologic type.
- For 61 CC (stage I: 28; II: 10; III: 22; IV: 1), we investigated the relationship between ABCF2 expression and the response to chemotherapy or OS. The percentage of positive cytoplasmic staining (Labeling index (LI)) for ABCF2 was calculated. In 28 CC patients,

quantitative RT-PCR was performed to evaluate the relationship between relative mRNA expression and protein expression.

Results:

1. CC had significantly higher levels of ABCF2 expression than other histologic type.
2. Fifty six CC patients received platinum-based chemotherapy after primary debulking surgery and the response to chemotherapy was evaluable in 12 of them.
3. Forty three of 61 (70.5%) patients showed ABCF2 expression and the relative mRNA expression was significantly correlated with levels of ABCF2 protein expression ($r = 0.5$, $p = 0.006$).
4. A clinical response to chemotherapy was obtained in 5 of 12 (42%) cases.
5. Non responders had significantly higher levels of ABCF2 protein expression than responders (59% vs 25%, $p = 0.0007$).
6. The OS was 75% (median follow-up of 36 months). The OS for patients without ABCF2 expression was significantly higher than the OS for patients with ABCF2 expression (94% vs 67%, $p = 0.03$).

Conclusions: The present results indicate that ABCF2 expression may predict the response to chemotherapy and survival of CC patients.

913

POSTER

Plasminogen Activator Inhibitor-1 RNA Binding Protein expression in epithelial ovarian cancer

D. Koensgen¹, A. Mustea¹, E. Dahl³, I. Klamann⁴, B. Petschke¹, P. Sun², W. Lichtenegger¹, J. Sehouli¹. ¹Charité, Medical University Berlin, Gynaecology and Obstetrics, Berlin, Germany; ²Peking, University People's Hospital, Gynaecology and Obstetrics, Beijing, China; ³Medical University, Institute of Pathology, Aachen, Germany; ⁴MetaGen Pharmaceuticals, Berlin, Germany

Background: The plasminogen activator-plasmin cascade plays a central role in tumor cell invasion and metastasis of solid tumors. The type-1 plasminogen activator inhibitor (PAI-1) is the major physiologic regulator of the plasminogen activation. The novel Plasminogen Activator Inhibitor-1 RNA Binding Protein (PAI-RBP1) is suggested to play a crucial role in cyclic nucleotide-mediated regulation of PAI-1 mRNA stability. The expression of PAI-RBP1 in ovarian cancer is unknown. We are the first working group to analyse the expression of PAI-RBP1 in ovarian cancer.

Methods: Identification of overexpressed genes in ovarian cancer by in-silico analysis (AUTEX, e-NORTHERN, BLAST). In a second step analysis of the expression of PAI-RBP1 by in-situ hybridization was performed. Tissue sections of paraffin-embedded tumor specimens from patients with benign and malignant ovarian tumors, who underwent surgical intervention in the Department of Gynaecology and Obstetrics, Charité, from 02/01 to 06/02, were used. All samples were obtained from Tumor Bank Ovarian Cancer (TOC). Correlation analysis with conventional clinical factors was performed by using SPSS (SPSS Inc., V.11.0; Chicago 2001).

Results: 57 patients (28 primary ovarian cancer, 15 recurrent ovarian cancer, 3 low-malignant potential ovarian tumors, 6 benign ovarian tumors, 5 normal ovary) were allocated to this trial. Median age was 57 years (range, 34–86). Median follow-up was 20 months (range, 0–64). The distribution of tumor stage FIGO of all primary ovarian cancer was: I = 16.2%, II = 3.2%, III = 45.2% and IV = 35.5%. PAI-RBP1 was significantly overexpressed in tumor epithelium of ovarian cancer in comparison to ovarian epithelium of benign ovarian tumors and normal ovary ($p = 0.002$). In statistical analysis a significant correlation between the PAI-RBP1 expression and FIGO-stage was observed ($p = 0.014$).

Conclusions: PAI-RBP1 is significantly overexpressed in OC and correlates with the clinical tumor stage FIGO. The prognostic role of PAI-RBP1 will be analysed after a longer follow-up period.

914

POSTER

Shedding of GPI-anchored proteins from ovarian cancer cells promotes pericellular plasmin generation and cell invasion

G. Brunner¹, D. Thormeyer¹, J.H. Howard², K. Kampmann¹. ¹Fachklinik Hornheide, Department of Cancer Research, Münster, Germany; ²University of Manchester, Faculty of Life Sciences, Manchester, United Kingdom

Background: In human ovarian cancer, soluble forms of glycosylphosphatidylinositol (GPI)-anchored proteins (e.g. the protease receptor, urokinase receptor [uPAR], and CA125) accumulate in the ascitic fluid and the blood of the patients, and their concentration has prognostic significance. uPAR regulates cell surface plasmin generation. We have shown previously that GPI-anchored proteins are released from ovarian cancer cells in vitro by GPI anchor hydrolysis catalyzed by cellular GPI-specific phospholipase D (GPI-PLD). Here, we describe the role of this

enzymatic event in regulating pericellular proteolysis and ovarian cancer cell invasion.

Materials and methods: Transfections with cDNA constructs and siRNA were performed using Lipofectamine Plus. Stable cDNA transfectants were isolated by G418 selection and cloned by limiting dilution. Plasmin generation was determined using the chromogenic substrate, S-2251. Cell invasion was measured using a double-filter assay and fibrin or the basement membrane extract, matrigel, as substrates.

Results: By targeting GPI-PLD expression in human OV-MZ-13 ovarian cancer cells using stable antisense cDNA transfection, uPAR shedding was reduced up to 4-fold in selected antisense clones as compared to control clones. Cell invasion into fibrin (80% inhibition with non-cloned antisense transfectants) or matrigel (93% inhibition with antisense clones), was almost completely abolished by GPI-PLD antisense targeting. Similar inhibitory effects were seen with GPI-PLD-specific siRNAs, which reduced GPI-PLD expression approximately 4-fold. Inhibition of cell invasion by GPI-PLD antisense targeting appeared to be caused by two distinct effects: (i) Reduction in cell surface uPAR expression (45% inhibition) and plasminogen activation (30% inhibition), which was most likely due to the diminished formation of the bioactive GPI anchor cleavage product, phosphatidic acid. Exogenous phosphatidic acid increased uPAR expression 2-fold. (ii) Decrease in extracellular-matrix associated plasmin generation (up to 84% at the conal level) due to reduced uPAR shedding (75% inhibition) and soluble uPAR binding to matrigel (53% inhibition).

Conclusions: Shedding of GPI-anchored proteins enhances cell surface and pericellular proteolysis and is required for ovarian cancer cell invasion. Thus, GPI-PLD is a malignant property of ovarian cancer cells with potential significance as a prognostic marker and/or therapeutic target.

915

POSTER

Paclitaxel/Carboplatin (TC) versus Paclitaxel/Carboplatin followed by Topotecan (TOP) in first line treatment of advanced ovarian cancer. Mature results of a Gynecologic Cancer InterGroup (GCIg) phase III trial of the AGO OVAR and GINECO

E. Pujade-Lauraine, H. Meden, A.C. Hardy-Bessard, U. Nitz, M. Mousseau, J.U. Blohmer, M. Flesch, A. Stähle, F. Mefti, J. Pfisterer. For the GINECO, France and AGO-OVAR, Germany study groups

Background: A randomized phase III trial was performed in patients (pts) with advanced ovarian cancer (OC) to determine the role of Top in first line treatment. The sequential manner was chosen to incorporate Top as a non cross resistant third drug to TC by avoiding the toxicity of a simultaneous triple drug regimen.

Material and methods: Between 12/1999 and 03/2002 1,308 pts with previously untreated OC FIGO stages IIB–IV were randomized to receive 6 cycles of Paclitaxel (175 mg/m² 3h iv) and Carboplatin (AUC 5, Calvert formula) (TC) followed by surveillance or 4 cycles of Topotecan (1.25 mg/m² iv d1–5) (Top) on a 3 week schedule. Pts were stratified within each center according to residual tumor size and FIGO stage: stratum 1 "FIGO stage IIB–IIIC and residual tumor ≤ 1 cm", and stratum 2 "FIGO stage IIB–IIIC and residual tumor > 1 cm or FIGO IV". The primary endpoint was overall survival (OS). This study was designed to show an increase in 3 year survival of 8% with a power of 80% using a stratified log-rank test with alpha set to 5%. To detect this effect at least 541 events were necessary.

Results: 658 pts were assigned TC followed by Top and 650 TC. Overall, 9453 treatment cycles were administered, 5564 in the TC-Top arm and 3889 in the TC arm. During treatment with TC, no relevant difference in Grade (G) 3/4 hematologic and non-hematologic toxicity between both study arms was observed. The median doses of TC were given as scheduled, as were the median intervals between therapy courses. Top myelotoxicity resulted in treatment delays of at least 7 days in 18.4% of Top courses. G 3/4 anemia occurred in 6.4% of all Top courses, thrombocytopenia in 10.7%, leukocytopenia in 28.0% and neutropenia in 57.0%. However, this was of minimal clinical relevance in terms of febrile neutropenia (0.9%) or infections (0.9%) in pts treated with Top. Median Top dose/course/day for all courses was 1.25 mg/m². Response data were available from 145 and 147 pts with measurable disease in the TC-Top and TC arm. TC-Top was associated with 69.0% clinically complete and partial responses; TC with 76.2% (ns). 947 of the 1308 pts had progressed and 625 pts had died. PFS for pts with/without Top was 18.2 months vs. 18.5 months, corresponding to an adjusted HR of 0.97 (95%-CI 0.85–1.10, $p = 0.688$). There was also no significant difference in overall survival with a median of 43.1 months in the TC-Top arm and 44.5 months in the TC arm (adjusted HR = 1.01, 95%-CI 0.86–1.18, $p = 0.885$).

Conclusions: The addition of Top to TC did not result in superior OR, PFS and OS. Therefore, TC-Top cannot be recommended as first-line therapy of advanced OC.